Cybin (HELP) Income from Non-Controlling Interests (2020 - 2024)
Cybin (HELP) posted quarterly Income from Non-Controlling Interests of $715.85 for Q4 2024, down 67.45% on a QoQ basis from $2199.2 in Q3 2024.
Cybin (HELP) Income from Non-Controlling Interests (2020 - 2024) Analysis & Trends
Cybin (HELP) has reported Income from Non-Controlling Interests for 4 consecutive years, with $715.85 the latest figure, recorded in Q4 2024.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $715.85 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.7 million (changed N/A YoY) and the FY2021 annual result came in at $53757.5, changed N/A from the prior year.
- Income from Non-Controlling Interests fell to $715.85 in Q4 2024 per HELP's latest filing, from $2199.2 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for HELP reached as high as $25219.3 in Q2 2021 and fell as low as -$1.7 million in Q3 2022.
- A 4-year average of -$254386.7 and a median of $1442.4 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests jumped 1648.42% — and 2022, when it tumbled 1000.81%.
- Year by year, Income from Non-Controlling Interests stood at $1442.4 in 2020, then plunged by 10564.29% to -$150937.8 in 2021, then slumped by 1000.81% to -$1.7 million in 2022, then surged by 100.04% to $715.85 in 2024.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $715.85, $2199.2, and $2193.4 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 715.85 |
| Sep 30, 2024 | 2,199.16 |
| Jun 30, 2024 | 2,193.42 |
| Sep 30, 2022 | -1.66 Mn |
| Sep 30, 2021 | -150,937.77 |
| Jun 30, 2021 | 25,219.34 |
| Jun 30, 2020 | 1,442.41 |